KENILWORTH, N.J., Jun 01, 2015 (BUSINESS WIRE) — Merck MRK, -0.36% known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer (SCLC), esophageal cancer and ovarian cancer from the KEYNOTE-028 Phase 1b study.
http://www.marketwatch.com/story/findings-presented-at-2015-asco-annual-meeting-add-to-breadth-of-keytruda-pembrolizumab-data-anti-tumor-activity-now-demonstrated-in-13-different-tumor-types-2015-06-01
Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types